Lucio Nobile
Medical Oncology · Fresno, CANPI 1396828588
Payments from drug & device makers
Across 133 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$835
- Pfizer$259
- Johnson & Johnson$210
- AstraZeneca$175
- Incyte Corporation$144
- E.r. Squibb & Sons, L.L.C.$132
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,48878%
- Education$371%
- Other$68221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $835 |
| Pfizer | 18 | $259 |
| Johnson & Johnson | 11 | $210 |
| AstraZeneca(2 entities) | 8 | $175 |
| Incyte Corporation | 7 | $144 |
| E.r. Squibb & Sons, L.L.C. | 7 | $132 |
| Amgen | 4 | $110 |
| Sobi, Inc | 4 | $106 |
| Bristol Myers Squibb | 5 | $105 |
| Merck | 5 | $99 |
| Rigel Pharmaceuticals, Inc. | 4 | $76 |
| Genentech USA, Inc. | 3 | $62 |
| Global Blood Therapeutics, Inc. | 3 | $62 |
| GSK | 2 | $57 |
| Puma Biotechnology, Inc. | 3 | $54 |
| Lilly USA, LLC | 3 | $53 |
| Seagen Inc. | 3 | $51 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $50 |
| Bayer | 2 | $42 |
| Karyopharm Therapeutics Inc. | 2 | $37 |
| Emmaus Medical, Inc. | 1 | $34 |
| Beigene USA, Inc. | 1 | $31 |
| Eisai Inc. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $28 |
| Adaptive Biotechnologies Corporation | 1 | $27 |
| Boehringer Ingelheim | 2 | $27 |
| Exelixis Inc. | 1 | $26 |
| AMAG Pharmaceuticals, Inc. | 1 | $25 |
| Sanofi | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| AbbVie | 1 | $21 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| GE HealthCare | 1 | $15 |
| Secura Bio, Inc. | 2 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $11 |
How this compares
$3,206 in reported general payments places this provider in the 30th percentile of 379 medical oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 106 | $1,216,580 |
| IbrancePalbociclib | 54 | $834,094 |
| XtandiEnzalutamide | 60 | $728,821 |
| PomalystPomalidomide | 20 | $485,893 |
| TagrissoOsimertinib Mesylate | 27 | $465,105 |
| KisqaliRibociclib Succinate | 36 | $418,515 |
| CabometyxCabozantinib S-Malate | 20 | $332,298 |
| CalquenceAcalabrutinib Maleate | 20 | $287,566 |
| LynparzaOlaparib | 12 | $201,308 |
| BrukinsaZanubrutinib | 19 | $157,869 |
| OrgovyxRelugolix | 12 | $30,979 |
| Abiraterone Acetate | 101 | $15,952 |
| EliquisApixaban | 14 | $12,602 |
| Anastrozole | 71 | $1,989 |
| Dexamethasone | 111 | $1,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence, Lynparza | $175 | $953,98059 claims |
| PfizerIbrance, Eliquis | $259 | $846,69668 claims |
| Astellas Pharma US IncXtandi | $18 | $728,82160 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $132 | $485,89320 claims |
| NovartisKisqali | $835 | $418,51536 claims |
| Exelixis Inc.Cabometyx | $26 | $332,29820 claims |
| Beigene USA, Inc.Brukinsa | $31 | $157,86919 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $18 | $1,03949 claims |
| Lilly USA, LLCOlanzapine | $53 | $10016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 379 medical oncology providers in California.
Other medical oncology in Fresno
- Sarmad SadeghiLos Angeles$26.1M
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Farshid DayyaniOrange$13.4M
- Daneng LiDuarte$12.4M
- Heinz-Josef LenzLos Angeles$11.6M
- Kevin KimSan Francisco$10.8M
- Anthony El-KhoueiryLos Angeles$10.5M
- Amy ChienSan Francisco$10.5M
- Sandhya SrinivasStanford$10.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.